Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prevention of regorafenib-associated hand-foot syndrome with aluminum chloride and wound dressing
jRCTs031180096Completed
- Sponsor
- Sumitomo Mitsui Trust
- Start
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of regorafenib and aluminum chloride in colorectal cancer (CRC), sponsored by Sumitomo Mitsui Trust. Primary endpoint: Incidence of Grade 3 hand-foot syndrome. Started Feb 2019; status: completed.
02
Drugs
regorafenibaluminum chloride
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on jRCTs031180096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180096.